Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Request for a sample report to understand more about the Aplastic Anemia pipeline development activities @ https://www.delveinsight.com/sample-request/aplastic-anemia-market
Aplastic Anemia Therapeutics Assessment
Major key companies are working proactively in the Aplastic Anemia Therapeutics market to develop novel therapies which will drive the Aplastic Anemia treatment markets in the upcoming years are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and Many Others.
Learn more about the emerging Aplastic Anemia therapies & key companies @ https://www.delveinsight.com/sample-request/aplastic-anemia-market
End
This segment gives a thorough detail of the Aplastic Anemia market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Aplastic Anemia market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Aplastic Anemia market in 7MM is expected to witness a major change in the study period 2020-2034.
Aplastic Anemia Epidemiology
The Aplastic Anemia epidemiology section provides insights into the historical and current Aplastic Anemia patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Aplastic Anemia market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Aplastic Anemia Epidemiology @ Aplastic Anemia Market Dynamics
Aplastic Anemia Drugs Uptake
This section focuses on the uptake rate of the potential Aplastic Anemia drugs recently launched in the Aplastic Anemia market or expected to be launched in 2020-2034. The analysis covers the Aplastic Anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Aplastic Anemia Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Aplastic Anemia market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Aplastic Anemia Pipeline Development Activities
The Aplastic Anemia report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Aplastic Anemia key players involved in developing targeted therapeutics.
Con’t
Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin (r-ATG) and Cyclosporine a (CsA) in East-Asian Patients With Treatment Naive Severe Aplastic Anemia (REACTS). *On August 2023, Kyowa Kirin Co., Ltd announced results of a Long Term Follow-up Observational Study after Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia.
Aplastic Anemia Overview
Aplastic anemia is a rare but serious blood disorder characterized by the inability of the bone marrow to produce enough blood cells. This deficiency results in a decrease in red blood cells, white blood cells, and platelets, leading to symptoms such as fatigue, weakness, frequent infections, and easy bruising or bleeding. The condition can be acquired due to exposure to toxins, certain medications, infections, or autoimmune disorders, or it can be inherited. Diagnosis typically involves blood tests, bone marrow biopsy, and other specialized tests. Treatment options vary depending on the severity and cause of the aplastic anemia but may include blood transfusions, medications to stimulate blood cell production, immunosuppressive therapy, or bone marrow transplant. Close monitoring and ongoing medical care are essential for managing the condition and minimizing complications.
Learn more about Aplastic Anemia treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/aplastic-anemia-market
Aplastic Anemia Market
The Aplastic Anemia market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Aplastic Anemia market trends by analyzing the impact of current Aplastic Anemia therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
Con’t ….
Full Article 👍
Aplastic Anemia Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies, Companies & Growth Analysis Report by DelveInsight
M2 Communications
2nd May 14:35
Leading Aplastic Anemia companies working in the market are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and Many Others. *Leading Aplastic Anemia companies working in the market are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell,...
Leading Aplastic Anemia companies working in the market are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and Many Others.
(Albany, USA) DelveInsight's "Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Aplastic Anemia, historical and forecasted epidemiology as well as the Aplastic Anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Aplastic Anemia market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Aplastic Anemia market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Aplastic Anemia treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Aplastic Anemia market.
Request for a Free Sample Report @ Aplastic Anemia Market Forecast
Some facts of the Aplastic Anemia Market Report are:*According to DelveInsight, Aplastic Anemia market size is expected to grow at a decent CAGR by 2034. *In the 7MM, United States accounted for the largest Aplastic Anemia Market Size in 2023, with approximately USD ~190 million. *Leading Aplastic Anemia companies working in the market are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and Many Others. *Key Aplastic Anemia Therapies expected to launch in the market are PF-06462700, REGN7257, BL-8040, and Others. *On April 2024, Rocket Pharmaceuticals announced results of a Phase 2 Clinical Trial to Evaluate the Efficacy of the Infusion of Autologous CD34+ Cells Transduced with a Lentiviral Vector Carrying the FANCA Gene in Pediatric Subjects with Fanconi Anemia Subtype A. *On March 2024, Regeneron Pharmaceuticals announced results of a Phase 1/2 Study of REGN7257 (Anti-Interleukin 2 Receptor Subunit Gamma [IL2RG] Monoclonal Antibody) in Patients with Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy. *On February 2024, Novartis announced results of a Non-randomized, Open Label, Multi-center,
Con’t…
Afternoon all
Hemo mentioned on Ortex will post full article if anyone fancy’s a read with a cuppa 👍
Aplastic Anemia Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Epidemiology, Therapies, Companies & ...
World News
2nd May 13:04
"Aplastic Anemia Market" Leading Aplastic Anemia companies working in the market are Pfizer, BioLineRx, Ltd., Regeneron Pharmaceuticals, Gamida
Cell, Elixirgen, Hangzhou Zede Pharmaceutical Technology, Cellenkos, Hemogenyx Pharmaceuticals, and Many Others. (Albany, USA) DelveInsight's "Aplastic read full story
Aplastic Anemia Market Insights, Epidemiology, and Market Forecast-2034
In the abscence of clearer updates from hemo, you are the next best thing so thank you again Haywain
Last point, on CART I remember you outlined the steps required to get CART to actual trials. Do you feel that the proactive interview stating results by Dec was too conservative and you would have expected trials to have started by now or close to and results by say Sept? Or am I being too positive for once?
That is impossible to say - put it this way I wouldn't be surprised to get further updates from CBR it seems like they put a lot of work into developing an off the shelf solution to virus X last year by chosing an mRNA construct, stabilising it with nano- polymers and developing a aerosol mode of delivery. They could have decided to do this off their own bat but to me I link these sorts of requirements with DARPR. So I wouldn't be surprised if some sort of matched funding was announced to further develop CBR for government use. I don't expect to hear anything on CDX until we get clinical data back from CAR-T personally .
Excellent post Haywain, and we can only hope you are right re the funds. Vlad won’t give away too much of his company in order to set out his goals, but he may have to be more flexible than he’s been in the past
Haywain ... Thats a fair and honest perspective of things. I am also sticking around until trials start and the 1st batch of results shows hopefully positive feedback. Of course, anyone buying at this price now will be quids in by then and thats the gamble of waiting it out or waiting till nearer and getting in then but at a higher price and once funds (Hopefully) materialise.
Do you believe that as per the proactive interview, the real rewards will come in Q4 when trial results are expected or do you foresee some other updates on CART or CDX/CBR before then? This question is not a share price question but what news do you expect to hear about based on what u know about Hemo
"so it would have to be moving from 1 isa to another?" - not necessarily. It could also be from a fund and share trading account. I've done this previously to avoid paying tax on gains.
In fairness mr India irrespective of what the share price is, there is an intrinsic value to Hemogenyx's pipeline of products that can only be estimated by comparison to other companies developing similar products for similar indications. The one aspect that Hemo seem to have set against them is their ability to raise funds (at a reasonable price) which would factor into valuation because that is one thing they will need plenty of to continue with the clinical program. I have very little doubt over the science which I think is excellent and somewhat revolutionary. For me (as someone that is positive about Hemo's future) I am essentially betting that those funds will materialise due to the nature of the products being developed by Hemo whether that be in dilutive or non-dilutive form. The shorters are betting that they wont be able to access funds or if they do it will be dilutive and at an ever decreasing share price. Who will be right? I am hanging around to find out!
Lets be honest and realistic here. Even though is a downright shorter and disgusting person who shorted this down after FDA approval, he is right that we cannot just say this is worth X because another CART company is worth X and has become clinical. The science is awesome we know that. We know there is money in the bank and it should last 9 months BUT as a new investor or even LTHs who are considering averaging down, why would you :
- We dont have any update on trials and not even a whiff of news in the recent trading update
- We have been told that they expect results by Dec and 1 patient may be done by then
- We know there are 1.4bn shares in issue thanks to continous placing by our illustrious and caring CEO
- Not a single director has purchased any shares at this low price
- CBR and CDX are a long way from being real
So why would you block money like i have for another say 9 months ... I tell you why:-
- Because this is as low as it should go so if you have a 6 month horizon its worth a punt
- If news comes and its not a pump and dump, this will fly again
- The market is subdued and trust is low with vlad but that can change once licencing or funds are injected
So yes this is going to be a long boring ride but I think most agree that due to FOMO they cannot leave now and come back when this is over 10p !!!
@Mattpr1
"so it would have to be moving from 1 isa to another?"
The above is exactly my understanding of what a bed/ISA situation is.
But I'm not an expert either, so could be wrong
"Anyway.. sp is red, thats the bottom line"
I am afraid that will remain so until demand surpass supply.
I can't see that there is anyone to blame for that, it is what it is and there is not much we can do about it, other then be patient if we still want to participate in this journey.
I thought the market would wake up when the clinical hold would be lifted and we became clinical and there was some financial security.
All of the above has happened and on top of that we have had great news regarding the development of our different products.
At some point the market will get a appetite for risk and there will be a higher demand, but when will that happen and what news will it take?
I got no clue.
As said earlier, I had expected to already have happened.
But its the same amount, so it would have to be moving from 1 isa to another? Im not an expert, maybe theres a way to up the ante. Use partners limit etc. Anyway.. sp is red, thats the bottom line
We had news on Jan 23 and then this went flat whilst awaiting for new. This seems to following the same pattern. Check out the graph on Google.
@Mattpr1
Are you sure it's to big for bed/ISA?
I agree that any buys over 20.000 pounds are unlikely to someone using the new tax years allowance.
But we can all sell whatever we have of other shares in our ISA and buy HEMO shares for let's say 64.000 pounds.
Regarding the bed/ISA situation, my understanding has always been that it is the only way to move from one dealer to another.
Ergo, it has nothing to do with a tax years maximum allowance.
It is not a bed / isa, it is not 2 large buys.
It is simple really, it is just a rollover.
Matt ... you could be right as I put in a dummy buy for £64k on IG and i could but that much for 1.62p ... Just shows how much volume vlad has created for his trusted investors. At least someone is mopping up but looks like needs some really big news to make this move.
Too big for a bed/ isa
You will be able to get out but not for long time and until trials have started or some news on funds / licencing comes. There is no hurry for people to invest at this stage since there are plenty of shares in issue and we all know the next bit of news will be a pump and then things will settle and drift. Just gotta play the long game ... I am frustrated as well as every day is no news but been here too long to throw away what we have waited for. Remember company is clinical and there will be some interest by pharma if there is a hint of positive trial news ... you can then sell i suspect for 5p+ which will be worth the pain
I don't want 2p and news. Having stupidity, I topped up between clinical and raise. 3p and I can get out of this sheet show
Looks like a bed and isa as the prices are very close ... surely if these were big simultaneous buys the price would be over 1.7p by now. Wishful thinking i feel sadly as everyone just wants news and 2p !!!
Definitely looks like 2 large buys there. Good to see, hope it's followed by many more large buys...
Maybe Tilly will enlighten us later whether it actually was the short closing ?
Dorset my thoughts , lets hope it is the short closing as it could finally put the bottom on this and enable some forward movement